Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Unibest FDF Pipeline

    2025-07-09

    Current list of finished dosage formulations open for global market distribution and technology transfer. Read More
  • Unibest NewCo & Licensing Pipeline

    2025-07-09

    Current list of Unibest's innovative drug assets open for global licensing, co-developement and/or NewCo. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 28 2025

    2025-07-28

    This week, there are 4 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's LIVDELZI, containing active ingredient SELADELPAR LYSINE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - GENENTECH INC's COTELLIC, containing active ingredient COBIMETINIB FUMARATE - ARCUTIS BIOTHERAPEUTICS INC's ZORYVE, containing active ingredient ROFLUMILAST Read More
  • After GLP-1: Can Amylin Analogs Build The Next Frontier in Diabetes Treatment?

    2025-07-24

    Explore the future beyond GLP-1 drugs in diabetes and obesity treatment with amylin analogs. This article dives into the clinical promise, market opportunities, key challenges, and licensing strategies for amylin-based therapies, highlighting why they may redefine the next wave of metabolic medicine. Learn how Unibest supports pharma companies in licensing and accelerating amylin drug development. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 21 2025

    2025-07-21

    This week, there are 12 drugs in the patent and exclusivity list. They are: - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - DUCHESNAY INC's OSPHENA, containing active ingredient OSPEMIFENE - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SENTYNL THERAPEUTICS INC's ZOKINVY, containing active ingredient LONAFARNIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's INCRUSE ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 14 2025

    2025-07-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO, containing active ingredient SACUBITRIL; VALSARTAN - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - SERVIER PHARMACEUTICALS LLC's TIBSOVO, containing active ingredient IVOSIDENIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's KRINTAFEL, containing active ingredient TAFENOQUINE SUCCINATE Read More
  • Cost is King: Why Small Molecule GLP-1 Drugs Are Gaining Popularity in Developing Countries

    2025-07-09

    This article explores the growing preference for small molecule GLP-1 receptor agonists in developing countries, driven by cost sensitivity, infrastructure limitations, and the need for scalable oral therapies for diabetes and obesity. It examines the economic and clinical advantages of small molecules over biologics, analyzes emerging market dynamics, and outlines how Unibest leverages its sourcing, regulatory, and export expertise to support global access. The piece also reviews current pipeline innovations and the future potential of affordable GLP-1 drugs in underserved regions. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 07 2025

    2025-07-07

    This week, there are 13 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's BIKTARVY, containing active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's VEMLIDY, containing active ingredient TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's GENVOYA, containing active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's DESCOVY, containing active ingredient EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - ANI PHARMACEUTICALS INC's VEREGEN, containing active ingredient SINECATECHINS - NOVARTIS PHARMACEUTICALS CORP's PROMACTA KIT, containing active ingredient ELTROMBOPAG OLAMINE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 30 2025

    2025-06-30

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - EAGLE PHARMACEUTICALS INC's RYANODEX, containing active ingredient DANTROLENE SODIUM - ULTRAGENYX PHARMACEUTICAL INC's DOJOLVI, containing active ingredient TRIHEPTANOIN - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE Read More
  • Total 14 pages  Go to Page
  • Go